U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07035158) titled 'DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis' on May 21, 2024.
Brief Summary: Owlstone Medical has demonstrated that the use of an Exogenous Volatile Organic Compound (EVOC) that targets specific metabolic processes linked to cirrhosis pathophysiology enables identification of subjects with cirrhosis with high accuracy compared to healthy controls. This approach relies on the oral administration of food additives that are metabolized in the liver resulting in volatile end-products exhaled in breath. The presence of liver cirrhosis alters the metabolism of these EVOC-probes altering the breath concentratio...